Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene (This gene does not contain this module)
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: RPLP2

Summary for RPLP2

Gene information	Gene symbol	RPLP2
	Ensembl ID	ENSG00000177600
	Entrez ID	6181
	Gene name	ribosomal protein lateral stalk subunit P2
	Synonyms	D11S2243E\|LP2\|MGC71408\|P2\|RPP2
	Gene type	protein_coding
	UniProtAcc	P05387

Top

Dataset with differentially expressed gene: RPLP2

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	-1.13263	1.24e-19
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	-0.58949	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	-0.603692	2.22e-30
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Progenitors	-0.593271	2.78e-08
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Plasma cells	-0.389294	2.50e-05
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	-0.612093	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	-0.292361	1.22e-06
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	-0.27139	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	-0.410747	1.39e-02
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	-0.270787	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	-0.377381	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	-0.265239	1.65e-08
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	-0.272694	1.44e-39
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	0.629889	3.23e-07
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	1.27729	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	-0.391597	1.97e-04
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	-0.330694	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Plasma cells	-0.749012	1.89e-41
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	-0.650583	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	-0.26684	2.34e-27
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	pDCs	-0.422546	2.12e-02
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Erythrocytes	-1.0144	2.04e-33
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	0.397424	3.21e-24
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	0.272897	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	-0.276706	7.20e-14
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	-0.351652	1.46e-14
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	0.772379	1.13e-08
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.271176	5.80e-05
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	-0.84214	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Erythrocytes	-0.403452	7.48e-27
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	NK cells	-0.30172	2.43e-22
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	NK cells	-0.472697	1.16e-21
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	-0.68101	0.00e+00
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	0.532394	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	-0.745044	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD8+ T cells	-0.28835	2.77e-06
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD4+ T cells	-0.489348	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	0.283116	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	0.257901	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	-0.421206	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	0.596121	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-1.69544	2.31e-09
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	NK cells	-0.38328	2.86e-16
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD4+ T cells	0.268576	3.59e-02
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	Mono/Macro	-0.633059	2.63e-04
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	0.359429	0.00e+00
GSE104987	MCF7 cell line	Cell line	Breast cancer	ER+ breast cancer	Targeted therapy	KDM5-C70	NA	Malignant cells	0.321298	5.40e-30
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	0.921263	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	-2.68732	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	-2.72272	0.00e+00

Top

Expression of RPLP2 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to RPLP2

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating RPLP2

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Top

Motifs and transcription factors (TFs) regulating RPLP2

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
RPLP2	transfac_public__M00278	GATA1; LDB1; LMO2; TAL1; TCF3 (inferredBy_Orthology).
RPLP2	transfac_pro__M01861	ATF1 (directAnnotation).
RPLP2	transfac_pro__M06342	ZNF329 (inferredBy_Orthology).
RPLP2	jaspar__MA0604.1	ATF1 (inferredBy_Orthology).
RPLP2	metacluster_52.10	GTF3C2; ZNF436 (directAnnotation).
RPLP2	transfac_pro__M05379	ZNF740 (inferredBy_Orthology).
RPLP2	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	ETS2 (directAnnotation).
RPLP2	transfac_pro__M06322	ZNF181 (directAnnotation).
RPLP2	nitta__CG18619_TCGAAG20NGA_KH_RTGACGTCAT_m1_c3u	CREBL2 (inferredBy_Orthology).
RPLP2	taipale_tf_pairs__HOXD12_TBX21_AGGTGTKAAGTCGTAAA_CAP_repr	HOXD12; TBX21 (directAnnotation).
RPLP2	jaspar__MA1933.1	SREBF2 (directAnnotation).
RPLP2	taipale_tf_pairs__ELK1_FOXI1_WGTTKMCGGAWRTN_CAP	ELK1; FOXI1 (directAnnotation).
RPLP2	taipale_tf_pairs__ETV2_SOX15_RSCGGAANNNNNNYWTTGT_CAP_repr	ETV2; SOX15 (directAnnotation).
RPLP2	transfac_pro__M05976	ZNF223 (directAnnotation).
RPLP2	stark__YGATAC	SIX1 (inferredBy_Orthology).
RPLP2	taipale_tf_pairs__ELF2_NATGCGGAAGTR_HT	ELF2 (directAnnotation).
RPLP2	taipale_cyt_meth__PITX2_YTAATCCN_FL	PITX2 (directAnnotation).
RPLP2	metacluster_16.7	SOX10; SOX11; SOX14; SOX14; SOX15; SOX18; SOX2; SOX2; SOX21; SOX21; SOX21; SOX7; SOX7; SOX7; SOX8; SOX8; SOX9; SRY (directAnnotation). SOX1; SOX1; SOX10; SOX21; SOX3 (inferredBy_Orthology).
RPLP2	jaspar__MA1509.1	IRF6 (directAnnotation).
RPLP2	tfdimers__MD00380	ARID3A; ING4 (directAnnotation).
RPLP2	jaspar__MA1562.1	SOX14 (directAnnotation).
RPLP2	taipale_tf_pairs__HOXB2_ETV4_ACCGGAAATGAN_CAP	ETV4; HOXB2 (directAnnotation).
RPLP2	taipale_tf_pairs__ETV2_NHLH1_NGCAGCTGCCGGAWRYN_CAP_repr	ETV2; NHLH1 (directAnnotation).
RPLP2	taipale_tf_pairs__PITX1_TBX21_AGGTGNGAARGGATTA_CAP_repr	PITX1; TBX21 (directAnnotation).
RPLP2	metacluster_34.4	ETS1; ETS1; ETS1; HCFC1; SIX5; SIX5; SIX5; SIX5; SMARCC2; SMARCC2; THAP11; THAP11; ZNF143; ZNF143; ZNF143; ZNF143 (directAnnotation). TBX2; THAP11; THAP11; ZNF143 (inferredBy_Orthology).
RPLP2	metacluster_34.3	EGR1; ETS1; SETDB1; SIX5; SIX5; ZNF143; ZNF76 (directAnnotation).
RPLP2	metacluster_34.1	ZNF143; ZNF143; ZNF143; ZNF76; ZNF76; ZNF76 (directAnnotation).
RPLP2	transfac_pro__M06259	ZNF91 (directAnnotation).
RPLP2	swissregulon__mm__E2f7	E2F7 (inferredBy_Orthology).
RPLP2	taipale_tf_pairs__MEIS1_ELF1_NTGCCGGAAGTN_CAP_repr	ELF1; MEIS1 (directAnnotation).
RPLP2	dbtfbs__GMEB1_K562_ENCSR928KOR_merged_N1	GMEB1 (directAnnotation).
RPLP2	kznf__ZNF343_Imbeault2017_OM_RCADE	ZNF343 (directAnnotation).
RPLP2	transfac_public__M00024	E2F1 (directAnnotation).
RPLP2	taipale_tf_pairs__ETV2_SOX15_RSCGGAANNNNNNNYWTTGT_CAP_repr	ETV2; SOX15 (directAnnotation).
RPLP2	taipale_tf_pairs__ERF_HOXA3_RSCGGAWNNNNNNNYMATTA_CAP_repr	ERF; HOXA3 (directAnnotation).
RPLP2	transfac_pro__M06678	ZNF287 (inferredBy_Orthology).
RPLP2	taipale_tf_pairs__HOXB2_ELK3_RSCGGAAGTMRTTA_CAP	ELK3; HOXB2 (directAnnotation).
RPLP2	taipale_tf_pairs__ELK1_HOXA1_RCCGGAAGTAATTA_HT	ELK1; HOXA1 (directAnnotation).
RPLP2	transfac_pro__M06349	ZNF629 (inferredBy_Orthology).
RPLP2	taipale_tf_pairs__ETV2_HOXA2_NCCGGAAGNNNNNNYMATTA_CAP	ETV2; HOXA2 (directAnnotation).
RPLP2	jaspar__MA0246.1	SIX1 (inferredBy_Orthology).
RPLP2	taipale_tf_pairs__TFAP4_MAX_NCAGCTGNNNNNNNCACGTGN_CAP_repr	MAX; TFAP4 (directAnnotation).
RPLP2	metacluster_153.1	SOX10; SOX15; SOX18; SOX2; SOX2; SOX4; SOX7; SOX8; SOX8; SOX9; SRY (directAnnotation). BBX; CFAP65; CFAP65; CFAP65; PINX1; PINX1; PINX1; PINX1; SOX10; SOX10; SOX10; SOX10; SOX10; SOX11; SOX11; SOX11; SOX11; SOX11; SOX12; SOX12; SOX12; SOX12; SOX12; SOX13; SOX13; SOX13; SOX13; SOX14; SOX14; SOX14; SOX14; SOX15; SOX15; SOX15; SOX15; SOX15; SOX17; SOX17; SOX17; SOX17; SOX18; SOX18; SOX18; SOX18; SOX2; SOX2; SOX2; SOX3; SOX3; SOX3; SOX3; SOX3; SOX30; SOX30; SOX30; SOX4; SOX4; SOX4; SOX4; SOX5; SOX5; SOX5; SOX5; SOX6; SOX6; SOX6; SOX6; SOX7; SOX7; SOX7; SOX7; SOX8; SOX8; SOX8; SOX8; SOX9; SOX9; SOX9; SOX9; SRY; SRY; SRY; SRY; SRY (inferredBy_Orthology).
RPLP2	hocomoco__PRGR_HUMAN.H11MO.1.A	PGR (directAnnotation).
RPLP2	metacluster_52.4	ZNF276; ZNF276 (directAnnotation). ZSCAN21 (inferredBy_Orthology).
RPLP2	transfac_pro__M06079	ZNF726 (directAnnotation).
RPLP2	metacluster_172.22	E4F1 (inferredBy_Orthology).
RPLP2	cisbp__M01725	SREBF2 (inferredBy_Orthology).
RPLP2	tfdimers__MD00070	HOXA13; PURA (directAnnotation).
RPLP2	cisbp__M00412	SIX6 (inferredBy_Orthology).

Page: 1 2 3

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."